Cencora, Inc. (COR) - Dilution Analysis

10-Q filing | 194.5M shares outstanding

10-Q filing | 193.8M shares outstanding

10-Q filing | 193.8M shares outstanding

8-K filing: Walgreens Boots Alliance Holdings LLC sold 1,081,885 shares of Common Stock under Rule 144 and Cencora, Inc. repurchased 204,491 shares of Common Stock.

10-Q filing | 193.8M shares outstanding

10-K filing | 198.5M shares outstanding

8-K filing: On August 1, 2024, the Selling Stockholder sold 3,398,929 shares of Common Stock under Rule 144.

10-Q filing | 198.3M shares outstanding

10-Q filing | 199.4M shares outstanding

8-K filing: On February 7, 2024, the Selling Stockholder sold 4,000,000 shares of Common Stock under Rule 144. After the sale and a repurchase, the Selling Stockholder owns 26,277,561 shares, representing approximately 13% of the 199,269,598 total outstanding shares.

10-Q filing | 200.1M shares outstanding

8-K filing: Steven H. Collis, Chairman, President and Chief Executive Officer of Cencora, Inc., adopted a pre-arranged Rule 10b5-1 stock trading plan to sell up to 129,054 shares of the Company's common stock through the exercise of vested stock options.

10-K filing | 202.5M shares outstanding

8-K filing: A Selling Stockholder entered into variable pre-paid forward sale contracts and the company repurchased 1,279,590 shares. After the repurchase, the Selling Stockholder owns 30,489,956 shares, representing approximately 15% of the 199,432,748 total outstanding shares.

10-Q filing | 202.3M shares outstanding

8-K filing: A selling stockholder entered into variable pre-paid forward sale contracts with financial institutions and then the company repurchased 275,984 shares.

8-K filing: A selling stockholder entered into variable pre-paid forward sale contracts with financial institutions, intending to deliver 4,590,000 shares of common stock in exchange for approximately $644 million. ($644.0M proceeds)

10-Q filing | 202.3M shares outstanding

10-Q filing | 204.0M shares outstanding

8-K filing: Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen Corporation, adopted a pre-arranged Rule 10b5-1 stock trading plan to sell up to 169,492 shares of the Company's common stock through the exercise of vested stock options.

8-K filing: On December 8, 2022, the Selling Stockholder sold 4,750,000 shares of Common Stock under Rule 144 of the Securities Act of 1933.

10-K filing | 208.5M shares outstanding

10-Q filing | 208.9M shares outstanding

10-Q filing | 209.2M shares outstanding

10-Q filing | 208.6M shares outstanding

10-K filing | 208.5M shares outstanding

8-K filing: Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen Corporation, adopted a pre-arranged Rule 10b5-1 stock trading plan to sell up to 329,345 shares of the Company's common stock.

10-Q filing | 208.9M shares outstanding

8-K filing: AmerisourceBergen Corporation completed the acquisition of Alliance Healthcare from Walgreens Boots Alliance, Inc. on June 1, 2021, paying a purchase price of approximately $6.5 billion, composed of $6.275 billion in cash and 2 million shares of Company common stock.

10-Q filing | 204.9M shares outstanding

8-K filing: Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen Corporation, adopted a pre-arranged Rule 10b5-1 stock trading plan to sell up to 202,181 shares of the Company's common stock.

10-Q filing | 204.7M shares outstanding

8-K filing: AmerisourceBergen Corporation entered into a Share Purchase Agreement with Walgreens Boots Alliance, Inc. to acquire the majority of WBA's Alliance Healthcare businesses for approximately $6.5 billion, comprised of $6.275 billion in cash and 2 million shares of AmerisourceBergen Corporation common stock.

10-K filing | 204.8M shares outstanding

10-Q filing | 203.7M shares outstanding

10-Q filing | 207.1M shares outstanding

10-Q filing | 206.0M shares outstanding